Botta A, Bonifazi E, Vallo L, Gennarelli M, Garrè C, Salehi L, Iraci R, Sansone V, Meola G, Novelli G
Department of Biopatologia e Diagnostica per Immagini, Tor Vergata University, Rome, Italy.
Acta Myol. 2006 Jun;25(1):23-33.
Myotonic dystrophies, the most common form of adult muscular dystrophy, comprise at least two forms, clinically and genetically heterogeneous. Myotonic dystrophy type 1 and type 2 are both caused by unstable repetitions in untranslated gene regions: a [CTG]n expansion in the 3' region of the DMPK gene on chromosome 19q13 (DM1) and [CCTG]n tetranucleotide repeat located in the first intron of the ZNF9 gene on chromosome 3q21 (DM2). DM clinical features are caused by a gain of functions RNA mechanism in which the CUG and CCUG repeats alter nuclear functions, including alternative splicing of shared genes. Southern blot and/or polymerase chain reaction PCR-based approaches allow the detection of DM mutations in almost 100% of cases, however, the expansion size and the elevated grade of somatic instability make molecular testing for DM a diagnostic challenge. The increased use of DNA testing for DM generates many questions regarding the indications and interpretations of the test which require standardized methods, routinely available in molecular genetic laboratories. Here, we propose Guidelines for the molecular diagnosis of DM1 and DM2 approved by the Italian Ministry of Health in 2005 (Piano Nazionale Linee Guida, PNLG). Best practice for DM molecular analysis in diagnostic application, presymptomatic and prenatal testing, using direct and indirect approaches are described, with particular attention focused on ethical, legal and social issues. Overviews of materials used in the molecular diagnosis, as well as internet resources, are also included.
强直性肌营养不良是成人肌营养不良最常见的形式,至少包括两种临床和基因均异质的类型。强直性肌营养不良1型和2型均由非翻译基因区域的不稳定重复序列引起:19号染色体长臂1区3'端DMPK基因中的[CTG]n扩增(DM1),以及3号染色体长臂2区1带ZNF9基因第一内含子中的[CCTG]n四核苷酸重复序列(DM2)。DM的临床特征是由一种功能获得性RNA机制引起的,其中CUG和CCUG重复序列改变核功能,包括共有基因的可变剪接。Southern印迹法和/或基于聚合酶链反应(PCR)的方法几乎能在100%的病例中检测到DM突变,然而,扩增大小和体细胞不稳定性的升高使得DM的分子检测成为一项诊断挑战。DM基因检测的日益广泛应用引发了许多关于检测指征和解读的问题,这需要分子遗传学实验室常规可用的标准化方法。在此,我们提出了2005年意大利卫生部批准的DM1和DM2分子诊断指南(国家指导方针计划,PNLG)。描述了在诊断应用、症状前检测和产前检测中使用直接和间接方法进行DM分子分析的最佳实践,特别关注伦理、法律和社会问题。还包括分子诊断中使用的材料概述以及互联网资源。